Filing Flows › Bausch Health Companies (BHC) › Guidance & outlook
Bausch Health Companies (BHC) guidance and outlook
Bausch Health Companies (BHC) raised its guidance on Oct 28, 2026: Revenue $11.0B–$11.2B for ; Revenue +7% to +9% for ; EBITDA $1.0B for ; EBITDA $1.0B for .
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | $11.0B–$11.2B | raised | |
| Revenue | +7% to +9% | raised | |
| EBITDA | $1.0B | reaffirmed | |
| EBITDA | $1.0B | reaffirmed | |
| Operating cash flow | $1.0B | reaffirmed |
From the earnings release filed Oct 28, 2026 (8-K on EDGAR).
Bausch Health Companies' latest quarter
Bausch Health Companies, Q3 2026: revenue $2.9B (+10% year over year), operating margin 33.4%, net earnings $436M, operating cash flow $814M. The chart follows the revenue to costs, profit and cash.
Questions
Did Bausch Health Companies raise or lower its guidance?
Bausch Health Companies (BHC) raised its guidance on Oct 28, 2026: Revenue $11.0B–$11.2B for ; Revenue +7% to +9% for ; EBITDA $1.0B for ; EBITDA $1.0B for .
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.